Regeneron Pharmaceuticals, Inc. (REGN) said the FDA has accepted for priority review a Biologics License Application for REGEN-COV to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The FDA has assigned a target action date of April 13, 2022. REGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using the company's VelocImmune and VelociSuite technologies.
REGEN-COV is an investigational medicine and has emergency or temporary pandemic authorizations in more than?40?countries, including the U.S. It is fully approved in Japan and conditionally approved in the UK. Earlier in the week, the European Medicines Agency accepted for review the Marketing Authorization Application for the same antibody cocktail, known as Ronapreve in the EU.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.